For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...
Alexion Pharmaceuticals (Nasdaq: ALXN) announced positive results today from its Phase 3 study of ALXN1210 for patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare, life-threatening blood ...
An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results